论文标题
Covid-19的康复血液治疗：当地捐助者足够吗？
Convalescent Blood Treatment for COVID-19: Are Local Donors Enough?
论文作者
论文摘要
COVID-19现在是全球大流行，有效的疫苗可能需要几个月的时间。 100年前，当医生开始治疗以康复（或康复）幸存者捐赠的血浆患者的治疗时，西班牙流感的死亡人数减弱。通过疗养血液产品（CBP）给药的被动免疫转移似乎代表了一种容易获得的途径，可缓解死亡率，加快恢复时间的加快，甚至针对SARS-COV-2病毒的预防。在这里，我们回顾了对CBP功效的挑战，并提出了传播动力学的图理论模型，该模型识别了COVID-19病例不断发展的枢纽。重要的是，该模型表明，与仅当地捐助者合并的CBP相比，CBP疗效可能取决于有效且分布的全球抽样方案。
COVID-19 is now a global pandemic, and an effective vaccine may be many months away. Over 100 years ago, Spanish flu fatalities were attenuated when doctors began treating patients with blood plasma donated by recovered (or convalesced) survivors. Passive immunity transfer via administration of convalesced blood product (CBP) appears to represent a readily available and promising avenue for mitigating mortalities, expediting recovery time, and even prophylaxis against the SARS-CoV-2 virus. Here, we review challenges to CBP efficacy, and present a graph theoretical model of transmission dynamics that identifies evolving hubs of COVID-19 cases. Importantly, this model suggests that CBP efficacy may rest on an efficient and distributed global sampling scheme as opposed to CBP pooled from local donors alone.
